CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (Amex: JAV - News) today announced that it has received marketing authorization approval in the United Kingdom for Dyloject®, Javelin’s proprietary injectable formulation of diclofenac sodium (75 mg/2ml). “Dyloject’s UK approval is a milestone in establishing Javelin as a commercial provider of novel solutions for acute pain management,” stated Dr. Daniel B. Carr, Javelin’s CEO and CMO. “Dyloject’s high efficacy, ease of administration by rapid intravenous (IV bolus) injection, quick onset, long shelf life, and favorable safety profile fulfill unmet medical needs while fitting perfectly with today’s practice of acute pain control.”
